Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 28, 2026
Indaptus Therapeutics, Inc. (INDP)
A forensic read on Indaptus Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Clean
Earnings quality
1
Forensic signals
-454.0%
ROE
$386M
Market cap
Indaptus Therapeutics, Inc. earns a C (Mixed — selective) forensic quality grade. 1 forensic signal was flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-79%Return on invested capital. Return on invested capital is -79% and steady — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
Key fundamentals
Free Cash Flow$-14.8M
Return on Equity-661.5%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Indaptus Therapeutics, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about INDP's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown
🔒Peer comparison + filing-change monitoring & alerts
No credit card · informational only, not investment advice · see the track record
← Browse all forensic stock analyses
Data from SEC EDGAR public filings · metrics as of Jun 28, 2026. Forensic signals flag probability, not certainty.